keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic castrate resistant prostate cancer

keyword
https://www.readbyqxmd.com/read/29666834/androgen-action-in-prostate-function-and-disease
#1
REVIEW
Partha P Banerjee, Subhadra Banerjee, Terry R Brown, Barry R Zirkin
Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland that is frequently found in aging men. Androgens are essential for the development and differentiated function of the prostate, as well as for proliferation and survival of prostatic cells. In man, dog and rodent, there are age-related decreases in serum testosterone. Despite the lower serum testosterone levels, benign prostatic hyperplasia increases with age in men and dogs, while age-dependent prostatic hyperplasia develops in the dorsal and lateral lobes of the rat prostate...
2018: American Journal of Clinical and Experimental Urology
https://www.readbyqxmd.com/read/29666783/development-of-neuroendocrine-prostate-cancers-by-the-ser-arg-repetitive-matrix-4-mediated-rna-splicing-network
#2
Ahn R Lee, Nicole Che, Jessica M Lovnicki, Xuesen Dong
While the use of next-generation androgen receptor pathway inhibition (ARPI) therapy has significantly increased the survival of patients with metastatic prostate adenocarcinoma (AdPC), several groups have reported a treatment-resistant mechanism, whereby cancer cells can become androgen receptor (AR) indifferent and gain a neuroendocrine (NE)-like phenotype. This subtype of castration-resistant prostate cancer has been termed "treatment-induced castration-resistant neuroendocrine prostate cancer" (CRPC-NE)...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29666302/targeting-galectin-1-impairs-castration-resistant-prostate-cancer-progression-and-invasion
#3
Tsung-Chieh Shih, Ruiwu Liu, Chun-Te Wu, Xiaocen Li, Wenwu Xiao, Xiaojun Deng, Zsofia Kiss, Ting Wang, Xiaojia Chen, Randy P Carney, Hsing-Jien Kung, Yong Duan, Paramita M Ghosh, Kit S Lam
PURPOSE: The majority of prostate cancer (PCa) patients who are treated with androgen deprivation therapy (ADT) will eventually develop fatal metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no effective durable therapies for patients with mCRPC. High expression of Galectin-1 (Gal-1) is associated with PCa progression and poor clinical outcome. The role of Gal-1 in tumor progression are largely unknown. Here we characterized Gal-1 functions and evaluated the therapeutic effects of a newly developed Gal-1inhibitor, LLS30, in mCRPC...
April 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29663669/preliminary-efficacy-and-tolerability-of-chemohormonal-therapy-in-metastatic-hormone-na%C3%A3-ve-prostate-cancer-the-first-real-life-experience-in-asia
#4
Darren M C Poon, Tim Chan, Kuen Chan, Michelle Chan, Eric K C Lee, Kitty Law, Daisy Lam
INTRODUCTION: A substantial survival benefit with chemohormonal therapy has been proven by the CHAARTED and STAMPEDE studies, and this clinical approach has emerged as the standard of care for patients with metastatic hormone-naïve prostate cancer (mHSPC). However, because its clinical efficacy and tolerability in Asian patients remains uncertain, this study aims to evaluate preliminary results of its use in Hong Kong. METHODS: The clinical records of mHSPC patients treated with chemohormonal therapy from all six public oncology centers in Hong Kong between January 2015 and July 2016 were reviewed...
April 16, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29662636/analysis-of-hematological-parameters-as-prognostic-markers-for-toxicity-and-survival-of-223-radium-treatment
#5
Asha Leisser, Marzieh Nejabat, Markus Hartenbach, Reza Agha Mohammadi Sareshgi, Shahrokh Shariat, Gero Kramer, Michael Krainer, Marcus Hacker, Alexander R Haug
223 Radium (223 Ra) has emerged as treatment prolonging survival in patients with metastatic castration-resistant prostate cancer (CRPC). As 223 Ra can cause hematotoxicity (HT), pre-existing hematopoiesis might influence the efficacy of 223 Ra and the rate of hematotoxicity, but as to our knowledge such data has not been published yet, we retrospectively conducted an analysis on patients receiving 223 Ra. 54 patients treated with 223 Ra had a median survival of 67 weeks, which was significantly reduced in patients with pre-existing Hb toxicity (Tox) grade 2 (48 weeks P = 0...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29661653/radium-223-in-the-treatment-of-bone-metastasis-in-patients-with-castration-resistant-prostate-cancer-review-and-procedure
#6
J Orcajo-Rincon, A P Caresia-Aróztegui, M Del Puig Cózar-Santiago, J R García-Garzón, M de Arcocha-Torres, R C Delgado-Bolton, M J García-Velloso, S Alvarez-Ruiz, A M García-Vicente
Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (223 Ra), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease...
April 13, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29656854/radical-prostatectomy-in-metastatic-castration-resistant-prostate-cancer-feasibility-safety-and-quality-of-life-outcomes
#7
Chad A Reichard, Justin R Gregg, Mary F Achim, Ana M Aparicio, Curtis A Pettaway, Louis L Pisters, John F Ward, John W Davis, Brian F Chapin
Ongoing prospective studies are evaluating treatment of the primary tumor in men with de novo metastatic prostate cancer (PCa). One potential benefit is prevention of morbidity from local progression. Thus, local therapy may be best applied selectively to men with local progression once resistance to first-line therapies has occurred. Here, we gather support for the hypothesis that radical prostatectomy (RP) is safe and preserves quality of life (QOL) when applied in men with metastatic castration-resistant PCa (mCRPC)...
April 12, 2018: European Urology
https://www.readbyqxmd.com/read/29651569/external-radiation-exposure-excretion-and-effective-half-life-in-177-lu-psma-targeted-therapies
#8
J Kurth, B J Krause, S M Schwarzenböck, L Stegger, M Schäfers, K Rahbar
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted therapy with 177 Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified. RESULTS: In total, 50 patients with mCRPC and treated with 177 Lu-PSMA-617 (mean administered activity 6...
April 12, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29644451/emerging-therapies-in-metastatic-prostate-cancer
#9
REVIEW
Daniel W Sonnenburg, Alicia K Morgans
PURPOSE OF REVIEW: In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy. RECENT FINDINGS: Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644181/radium-223-for-metastatic-castration-resistant-prostate-cancer-results-and-remaining-open-issues-after-the-alsympca-trial
#10
EDITORIAL
Isabel Heidegger, Renate Pichler, Axel Heidenreich, Wolfgang Horninger, Andreas Pircher
No abstract text is available yet for this article.
March 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29642359/re-cabazitaxel-versus-docetaxel-as-first-line-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer-a-randomized-phase-iii-trial-firstana
#11
https://www.readbyqxmd.com/read/29630065/erratum-economic-burden-of-the-management-of-metastatic-castrate-resistant-prostate-cancer-in-italy-a-cost-of-illness-study-corrigendum
#12
(no author information available yet)
[This corrects the article on p. 789 in vol. 9, PMID: 29263702.].
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29629866/prognostic-and-predictive-clinical-factors-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#13
Daniel W Yokom, John Stewart, Nimira S Alimohamed, Eric Winquist, Scott Berry, Stacey Hubay, Jean-Baptiste Lattouf, Helene Leonard, Carla Girolametto, Fred Saad, Srikala S Sridhar
INTRODUCTION: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel. METHODS: A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed...
April 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29626324/apalutamide-first-global-approval
#14
Zaina T Al-Salama
Apalutamide (ErleadaTM ) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC). It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens. In February 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC). Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochemically-relapsed PC...
April 6, 2018: Drugs
https://www.readbyqxmd.com/read/29626121/reproducibility-and-repeatability-of-semi-quantitative-18-f-fluorodihydrotestosterone-fdht-uptake-metrics-in-castration-resistant-prostate-cancer-metastases-a-prospective-multi-center-study
#15
Hebert Alberto Vargas, Gem M Kramer, Andrew M Scott, Andrew Weickhardt, Andreas A Meier, Nicole Parada, Bradley J Beattie, John L Humm, Kevin D Staton, Pat B Zanzonico, Serge K Lyashchenko, Jason S Lewis, Maqsood Yaqub, Ramon E Sosa, Alfons J van den Eertwegh, Ian D Davis, Uwe Ackermann, Kunthi Pathmaraj, Robert C Schuit, Albert D Windhorst, Sue Chua, Wolfgang A Weber, Steven M Larson, Howard I Scher, Adriaan A Lammertsma, Otto Hoekstra, Michael J Morris
18 F-fluorodihydrotestosterone (18 F-FDHT) is a radiolabeled analogue of the androgen receptor's primary ligand that is currently being credentialed as a biomarker for prognosis, response, and pharmacodynamic effects of new therapeutics. As part of the biomarker qualification process, we prospectively assessed its reproducibility and repeatability in men with metastatic castration-resistant prostate cancer (mCRPC). Methods: We conducted a prospective multi-institutional study of mCRPC patients undergoing two (test/re-test)18 F-FDHT PET/CT scans on two consecutive days...
April 6, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29623850/treatment-of-metastatic-castration-resistant-docetaxel-resistant-prostate-cancer-a-systematic-review-of-literature-with-a-network-meta-analysis-of-randomized-clinical-trials
#16
Davide Tassinari, Chiara Cherubini, Britt Roudnas, Emiliano Tamburini, Fabrizio Drudi, Emanuela Bianchi, Manuela Fantini, Francesco Montanari, Sergio Sartori
INTRODUCTION: To compare the efficacy of abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer. METHODS: An indirect comparison of overall survival (OS) and time to PSA progression among abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 was performed with a network meta-analysis. OS in the entire population of patients was the primary end point. OS in ECOG 0-1/2, BPI-SF≤4/>4, pretreated with 1 or 2 courses of chemotherapy, age≤65/>65 patients, patients with only bone metastases or bone and visceral metastases, and time to PSA progression were the secondary end points...
April 4, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/29616555/improvement-in-therapeutic-efficacy-and-reduction-in-cellular-toxicity-introduction-of-a-novel-anti-psma-conjugated-hybrid-antiandrogen-nanoparticle
#17
Chellappagounder Thangavel, Maryna Perepelyuk, Ettickan Boopathi, Yi Liu, Steven Polischak, Deepak A Deshpande, Khadija Rafiq, Adam P Dicker, Karen E Knudsen, Sunday A Shoyele, Robert B Den
Second generation antiandrogens have improved overall survival for men with metastatic castrate resistant prostate cancer; however, the antiandrogens result in suppression of androgen receptor (AR) activity in all tissues resulting in dose limiting toxicity. We sought to overcome this limitation through encapsulation in a prostate specific membrane antigen (PSMA)-conjugated nanoparticle. We designed and characterized a novel nanoparticle containing an antiandrogen, enzalutamide. Selectivity and enhanced efficacy was achieved through coating the particle with PSMA...
April 4, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29616091/molecular-and-cellular-mechanisms-of-castration-resistant-prostate-cancer
#18
REVIEW
Yiqiao Huang, Xianhan Jiang, Xue Liang, Ganggang Jiang
With increases in the mortality rate and number of patients with prostate cancer (PCa), PCa, particularly the advanced and metastatic disease, has been the focus of a number of studies globally. Over the past seven decades, androgen deprivation therapy has been the primary therapeutic option for patients with advanced PCa; however, the majority of patients developed a poor prognosis stage of castration resistant prostate cancer (CRPC), which eventually led to mortality. Due to CRPC being incurable, laboratory investigations and clinical studies focusing on CRPC have been conducted worldwide...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29615462/cell-free-dna-modification-dynamics-in-abiraterone-acetate-treated-prostate-cancer-patients
#19
Juozas Gordevičius, Algimantas Kriščiūnas, Daniel E Groot, Steven M Yip, Miki Susic, Andrew Kwan, Rafal Kustra, Anthony M Joshua, Kim N Chi, Art Petronis, Gabriel Oh
PURPOSE: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant prostate cancer, occurs in 20-40% of patients. We aim to identify predictive biomarkers for AA-treatment response and understand the mechanisms related to treatment resistance. EXPERIMENTAL DESIGN: We used the Infinium Human Methylation 450K BeadChip to monitor modification profiles of cell-free circulating DNA (cfDNA) in 108 plasma samples collected from 33 AA-treated patients...
April 3, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29610288/plasma-dna-and-metastatic-castration-resistant-prostate-cancer-the-odyssey-to-a-clinical-biomarker-test
#20
Anuradha Jayaram, Daniel Wetterskog, Gerhardt Attard
<b/> Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of TP53 or BRCA2 or ATM detected in plasma have significantly worse outcomes on novel AR targeting. Cancer Discov; 8(4); 392-4. ©2018 AACR. See related article by Annala et al., p. 444 .
April 2018: Cancer Discovery
keyword
keyword
58122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"